Skip to content

Usefulness of photochemotherapy and phototherapy in adult patients with white patches in Eastern India

Comparative efficacy of systemic PUVA versus NB-UVB in treatment of adult vitiligo in an eastern indian population: A double blind, randomized controlled trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2017/05/008473
Enrollment
56
Registered
2017-05-03
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Vitiligo

Interventions

Intervention1: PUVA: Trimethylpsoralen (0.6 mg/kg) with food, 2 hours before food on days of exposure. Standard initial dose of 2 J/cm2 started on all patients and increased by 0.5J/cm2 for each subse

Sponsors

Medical College Kolkata
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Nonsegmental vitiligo affecting > 5% and up to 70% of the body

Exclusion criteria

Exclusion criteria: 1. Age younger than 12years or older than 60years. 2. Previous skin malignancy, photodermatoses, SLE, porphyria, solar urticaria, photo contact dermatitis, previous failure of or intolerance to photo chemotherapy. 3. Treatment of vitiligo within last 3 months (phototherapy, systemic therapy, or topical therapy with corticosteroid agents, vitamin D analogues, or tacrolimus). 4. Pregnancy, lactation, renal or hepatic disease, lupus erythematosus, a history of photosensitivity, or administration of a drug known frequently to cause photosensitization. 5. History of hypersensitivity to any of the study drugs 6. Patients not willing to comply with protocol requirements

Design outcomes

Primary

MeasureTime frame
A. Effectiveness parameter by 1. Mean area of repigmentation 2. Vitiligo area scoring index 3. Patients global assessment of disease activity improvement (5 point Likert scale) 4. Physiciansâ?? global assessment of disease activity improvement (5 point Likert scale) 5. Graphical representation of Body Surface Area B. Safety of two treatment arms 1. Laboratory parameters 2. Adverse events noted by physician 3. Adverse events spontaneously reported by the patients Timepoint: A. Effectiveness parameters at 4th, 8th, 12th, 16th, 20th, 24th, 28th, 32nd, 36th, 40th, 44th, 48th follow-up visit B. Laboratory parameters at baseline, 24th and 48th follow-up visits

Secondary

MeasureTime frame
Quality of Life in both treatment arms by DLQITimepoint: Baseline and end of visit follow-ups

Countries

India

Contacts

Public ContactDr Karan Sancheti

Associate Professor Department of Dermatology Medical College, Kolkata

doc.s.n.chowdhury@gmail.com9433883407

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026